The FDA classifies drugs through several overlapping systems, each serving a different purpose. Some groupings describe what a drug does in the body, others determine whether you need a prescription, and still others affect how quickly the FDA reviews a new application. Understanding these systems helps make sense of the labels, restrictions, and designations you see attached to any medication.
Pharmacologic Class
The most fundamental way the FDA groups drugs is by pharmacologic class, which clusters medications that share scientifically documented properties. A pharmacologic class is built from any combination of three attributes of a drug’s active ingredient: its mechanism of action (how it works at a molecular level), its physiologic effect (what it does in the body), and its chemical structure.
For approved drugs, the FDA assigns what it calls an Established Pharmacologic Class, or EPC. This label appears in the highlights section of a drug’s prescribing information, right at the top. To earn an EPC, the class must meet two tests. First, it has to be scientifically valid, meaning there is real, documented evidence that the drug works the way its class label says it does, not just a theoretical assumption. Second, it has to be clinically meaningful, meaning it helps healthcare providers understand either the drug’s therapeutic effects or the side effects they should watch for. Statins, for example, are grouped as HMG-CoA reductase inhibitors because they all block the same enzyme involved in cholesterol production, and knowing that class helps predict both benefits and risks across the group.
New Molecular Entity vs. Existing Drug
When a company submits a drug for approval, the FDA classifies it based on whether the active ingredient is genuinely new. A New Molecular Entity (NME) is a drug whose active ingredient has never been approved or marketed in the United States before. This distinction matters because NMEs typically face more extensive review, since the FDA has no prior safety history to draw on. Drugs that use an already-approved active ingredient in a new formulation, new combination, or new dosage form go through a different track. The two main application types are the New Drug Application (NDA) for conventional drugs and the Biologics License Application (BLA) for biological products like vaccines and gene therapies.
Prescription vs. Over-the-Counter
Every approved drug falls into one of two access categories: prescription (Rx) or over-the-counter (OTC). The dividing line comes down to whether you can safely use the drug without a healthcare provider’s supervision. A drug stays prescription-only if its toxicity, potential for harm, method of use, or the monitoring it requires make self-treatment risky.
Drugs can move from prescription to OTC through a formal switch process. The company must submit safety and efficacy data showing the drug is safe for self-medication, plus evidence that everyday consumers can read the label and understand how to use it correctly on their own. The FDA approves the switch only when it determines that prescription status is no longer “necessary for the protection of the public health.” Familiar examples include ibuprofen and certain allergy medications, which were originally available only by prescription.
Controlled Substance Schedules
Drugs with potential for abuse get an additional layer of classification under the Controlled Substances Act, which places them into one of five schedules. Schedule I includes substances considered to have no accepted medical use and high abuse potential. Schedule II through V represent decreasing levels of abuse risk, with Schedule V drugs carrying the lowest potential. The Drug Enforcement Administration (DEA) makes the final scheduling decision, but the FDA plays a critical technical role: its Controlled Substance Staff assesses each drug’s abuse potential and provides that analysis to the DEA. This assessment considers factors like how the drug affects the brain, whether users develop dependence, and how it compares to substances already on the schedules.
Review Speed Designations
The FDA also classifies drug applications by how urgently they need to be reviewed. The two baseline categories are Standard and Priority.
A Standard review sets a target of 10 months for the FDA to act on the application. Priority review shortens that goal to 6 months and is reserved for drugs that treat serious or life-threatening conditions and would represent a significant improvement over existing therapies. “Significant improvement” can mean increased effectiveness, elimination of a major side effect that limits treatment, better patient compliance that leads to improved outcomes, or proven safety and effectiveness in a population that previously lacked good options.
Beyond priority review, the FDA has additional expedited pathways. Breakthrough Therapy designation is for drugs where early clinical evidence shows a substantial improvement over available treatments. Fast Track designation applies to drugs addressing serious conditions with an unmet medical need, and it allows the company to submit portions of its application on a rolling basis rather than all at once. Accelerated Approval lets the FDA approve a drug based on a surrogate marker (like tumor shrinkage) that is reasonably likely to predict a real clinical benefit, with the requirement that the company later confirms that benefit in further studies.
Orphan Drug Designation
Drugs developed for rare diseases can receive Orphan Drug designation. The threshold is straightforward: the disease or condition must affect fewer than 200,000 people in the United States. If a disease is common (200,000 or more people), a drug may still qualify for orphan designation if it targets a scientifically valid subset of patients within that disease. The designation comes with meaningful incentives for the manufacturer, including tax credits for clinical trial costs, waived application fees, and seven years of market exclusivity after approval. These incentives exist because the small patient population would otherwise make development financially unviable for most companies.
Pregnancy and Lactation Categories
For decades, the FDA classified drugs’ pregnancy risks using a simple letter system: A, B, C, D, and X, with A being safest and X meaning the drug should never be used during pregnancy. That system is gone. The Pregnancy and Lactation Labeling Rule (PLLR) replaced it because the letter grades oversimplified complex risks and often led to misinterpretation.
The current system requires three subsections in a drug’s label. The Pregnancy subsection includes a risk summary, clinical considerations, and supporting data, plus information about any pregnancy exposure registry that tracks outcomes in women who took the drug. The Lactation subsection (formerly “Nursing mothers”) provides specifics like how much of the drug passes into breast milk and what effects it could have on a breastfed infant. A third subsection, Females and Males of Reproductive Potential, is entirely new and covers whether pregnancy testing is recommended before starting the drug, contraception recommendations, and any effects on fertility. This narrative format gives a far more complete picture than a single letter ever could, though it does require more careful reading.